Sanofi Says FDA Approves Once-Weekly ALTUVIIIO for Hemophilia A

FDA approved ALTUVIIIO, a new class of factor VIII therapy for hemophilia A, Sanofi says.

• This is the first approval of ALTUVIIIO
• The FDA evaluated the application under Priority Review
• Regulatory submission in the EU is expected in 2H 2023

NOTE

• Sanofi shares were little changed as of last close
  • The average 12-month price target of EU103.90 is 15.3% above the current price
  • 17 buys, 12 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story: ...